A phase ii study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages ii and iii er+ her2+ breast cancer (paltan)

HIGHLIGHTS

• who: Foluso O. Ademuyiwa from the Patient eligibility Eligible patients included pre- and post-menopausal women at least , years old, with newly diagnosed AJCC , clinical stage II or III ER+/HER2+ invasive breast cancer with complete surgical excision after neoadjuvant therapy as the treatment goalTumors were required to be at least , cm in one dimension by clinical or World Health Organization radiographic exam. Additional inclusion criteria included an Eastern Cooperative Oncology Group of u22641, left ventricular ejection fraction u226550%, corrected QT interval andlt have published the research work: A phase II study of palbociclib plus letrozole plus . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.